Xilio Therapeutics, Inc. (NASDAQ:XLO) Position Increased by Renaissance Technologies LLC

Renaissance Technologies LLC grew its position in Xilio Therapeutics, Inc. (NASDAQ:XLO) by 18.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 295,000 shares of the company’s stock after purchasing an additional 45,554 shares during the period. Renaissance Technologies LLC owned about 0.80% of Xilio Therapeutics worth $280,000 at the end of the most recent quarter.

Xilio Therapeutics Price Performance

Shares of XLO stock opened at $0.80 on Friday. The firm has a market cap of $29.57 million, a P/E ratio of -0.31 and a beta of -0.10. The stock’s 50-day moving average is $0.82 and its two-hundred day moving average is $0.98. Xilio Therapeutics, Inc. has a fifty-two week low of $0.49 and a fifty-two week high of $2.89.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The firm had revenue of $2.36 million during the quarter, compared to analyst estimates of $30.00 million. As a group, research analysts expect that Xilio Therapeutics, Inc. will post -1.26 EPS for the current year.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.